PANVAC™-VF: poxviral-based vaccine therapy targeting CEA and MUC1 in carcinoma

Bibliography

• HILKENS J, KROEZEN V, BONFRER JM, DE JONG-BAKKER M, BRUNING PF: MAM-6 antigen, a new serum marker for breast cancer monitoring. Cancer Res. (1986) 46(5):2582-2587.
   PubMed Web of Science ®Google Scholar
• ROBBINS PF, EGGENSPERGER D, QI CF, SCHLOM J: Definition of the expression of the human carcinoembryonic antigen and non-specific cross-reacting antigen in human breast and lung carcinomas. Int. J. Cancer (1993) 53(6):892-897.
   PubMed Web of Science ®Google Scholar
• TENDLER A, KAUFMAN HL, KADISH AS: Increased carcinoembryonic antigen expression in cervical intraepithelial neoplasia grade 3 and in cervical squamous cell carcinoma. Hum. Pathol. (2000) 31(11):1357-1362.
   PubMed Web of Science ®Google Scholar
• LEVY B, PANICALLI D, MARSHALL J: TRICOM: enhanced vaccines as anticancer therapy. Expert Rev. Vaccines (2004) 3(4):397-402.
   PubMedGoogle Scholar
• TSANG KY, ZAREMBA S, NIERODA CA, ZHU MZ, HAMILTON JM, SCHLOM J: Generation of human cytotoxic T cells specific for human carcinoembryonic antigen epitopes from patients immunized with recombinant vaccinia-CEA vaccine. J. Natl Cancer Inst. (1995) 87(13):982-990.
   PubMed Web of Science ®Google Scholar
• EDER JP, KANTOFF PW, ROPER K et al.: A Phase I trial of a recombinant vaccinia virus expressing prostate-specific antigen in advanced prostate cancer. Clin. Cancer Res. (2000) 6(5):1632-1638.
   PubMed Web of Science ®Google Scholar
• GULLEY J, CHEN AP, DAHUT W et al.: Phase I study of a vaccine using recombinant vaccinia virus expressing PSA (rV-PSA) in patients with metastatic androgen-independent prostate cancer. Prostate (2002) 53(2):109-117.
   PubMed Web of Science ®Google Scholar
• HODGE JW, MCLAUGHLIN JP, KANTOR JA, SCHLOM J: Diversified prime and boost protocols using recombinant vaccinia virus and recombinant non-replicating avian pox virus to enhance T-cell immunity and antitumor responses. Vaccine (1997) 15(6-7):759-768.
   PubMed Web of Science ®Google Scholar
• MARSHALL JL, HOYER RJ, TOOMEY MA et al.: Phase I study in advanced cancer patients of a diversified prime-and-boost vaccination protocol using recombinant vaccinia virus and recombinant nonreplicating avipox virus to elicit anti-carcinoembryonic antigen immune responses. J. Clin. Oncol. (2000) 18(23):3964-3973.
   PubMed Web of Science ®Google Scholar
• AARTS WM, SCHLOM J, HODGE JW: Vector-based vaccine/cytokine combination therapy to enhance induction of immune responses to a self-antigen and antitumor activity. Cancer Res. (2002) 62(20):5770-5777.
   PubMed Web of Science ®Google Scholar
• HODGE JW, POOLE DJ, AARTS WM, GOMEZ YAFAL A, GRITZ L, SCHLOM J: Modified vaccinia virus ankara recombinants are as potent as vaccinia recombinants in diversified prime and boost vaccine regimens to elicit therapeutic antitumor responses. Cancer Res. (2003) 63(22):7942-7949.
   PubMed Web of Science ®Google Scholar
• GROSENBACH DW, BARRIENTOS JC, SCHLOM J, HODGE JW: Synergy of vaccine strategies to amplify antigen-specific immune responses and antitumor effects. Cancer Res. (2001) 61(11):4497-4505.
   PubMed Web of Science ®Google Scholar
• TSANG KY, PALENA C, YOKOKAWA J et al.: Analyses of recombinant vaccinia and fowlpox vaccine vectors expressing transgenes for two human tumor antigens and three human costimulatory molecules. Clin. Cancer Res. (2005) 11(4):1597-1607.
   PubMed Web of Science ®Google Scholar
• KASS E, PANICALI DL, MAZZARA G, SCHLOM J, GREINER JW: Granulocyte/macrophage-colony stimulating factor produced by recombinant avian poxviruses enriches the regional lymph nodes with antigen-presenting cells and acts as an immunoadjuvant. Cancer Res. (2001) 61(1):206-214.
   PubMed Web of Science ®Google Scholar
• GULLEY J, ARLEN P, DAHUT W et al.: A pilot study of a PANVAC-V and PANVAC-F in patients (pts) with metastatic carcinoma [abstract]. J. Clin. Oncol. (2006) 24(18S):2512.
   Google Scholar
• JEMAL A, SIEGEL R, WARD E et al.: Cancer statistics, 2006. CA Cancer J. Clin. (2006) 56(2):106-130.
   PubMed Web of Science ®Google Scholar
• PARAMORE LC, THOMAS SK, KNOPF KB, CRAGIN LS, FRAEMAN KH: Estimating costs of care for patients with newly diagnosed metastatic colorectal cancer. Clin. Colorectal Cancer (2006) 6(1):52-58.
   PubMed Web of Science ®Google Scholar
• KUTIKOVA L, BOWMAN L, CHANG S, LONG SR, OBASAJU C, CROWN WH: The economic burden of lung cancer and the associated costs of treatment failure in the United States. Lung Cancer (2005) 50(2):143-154.
   PubMed Web of Science ®Google Scholar
• MARSHALL JL, GULLEY JL, ARLEN PM et al.: Phase I study of sequential vaccinations with fowlpox-CEA(6D)-TRICOM alone and sequentially with vaccinia-CEA(6D)-TRICOM, with and without granulocyte-macrophage colony-stimulating factor, in patients with carcinoembryonic antigen-expressing carcinomas. J. Clin. Oncol. (2005) 23(4):720-731.
   PubMed Web of Science ®Google Scholar
• KARSTEN U, VON MENSDORFF-POUILLY S, GOLETZ S: What makes MUC1 a tumor antigen? Tumour Biol. (2005) 26(4):217-220.
   PubMed Web of Science ®Google Scholar
• KUFE D, INGHIRAMI G, ABE M, HAYES D, JUSTI-WHEELER H, SCHLOM J: Differential reactivity of a novel monoclonal antibody (DF3) with human malignant versus benign breast tumors. Hybridoma (1984) 3(3):223-232.
   PubMed Web of Science ®Google Scholar
• KLEE GG, SCHREIBER WE: MUC1 gene-derived glycoprotein assays for monitoring breast cancer (CA 15-3, CA 27.29, BR): are they measuring the same antigen? Arch. Pathol. Lab. Med. (2004) 128(10):1131-1135.
   PubMed Web of Science ®Google Scholar
• WEI X, XU H, KUFE D: Human MUC1 oncoprotein regulates p53-responsive gene transcription in the genotoxic stress response. Cancer Cell (2005) 7(2):167-178.
   PubMed Web of Science ®Google Scholar
• HUANG L, REN J, CHEN D, LI Y, KHARBANDA S, KUFE D: MUC1 cytoplasmic domain coactivates Wnt target gene transcription and confers transformation. Cancer Biol. Ther. (2003) 2(6):702-706.
   PubMed Web of Science ®Google Scholar
• AQUINO A, PRETE SP, GREINER JW et al.: Effect of the combined treatment with 5-fluorouracil, gamma-interferon or folinic acid on carcinoembryonic antigen expression in colon cancer cells. Clin. Cancer Res. (1998) 4(10):2473-2481.
   PubMed Web of Science ®Google Scholar
• WEI X, XU H, KUFE D: MUC1 oncoprotein stabilizes and activates estrogen receptor alpha. Mol. Cell (2006) 21(2):295-305.
   PubMed Web of Science ®Google Scholar
• HILTBOLD EM, ALTER MD, CIBOROWSKI P, FINN OJ: Presentation of MUC1 tumor antigen by class I MHC and CTL function correlate with the glycosylation state of the protein taken up by dendritic cells. Cell. Immunol. (1999) 194(2):143-149.
   PubMed Web of Science ®Google Scholar
• BENCHIMOL S, FUKS A, JOTHY S, BEAUCHEMIN N, SHIROTA K, STANNERS CP: Carcinoembryonic antigen, a human tumor marker, functions as an intercellular adhesion molecule. Cell (1989) 57(2):327-334.
   PubMed Web of Science ®Google Scholar
• ILANTZIS C, DEMARTE L, SCREATON RA, STANNERS CP: Deregulated expression of the human tumor marker CEA and CEA family member CEACAM6 disrupts tissue architecture and blocks colonocyte differentiation. Neoplasia (2002) 4(2):151-163.
   PubMed Web of Science ®Google Scholar
• HOSTETTER RB, CAMPBELL DE, CHI KF et al.: Carcinoembryonic antigen enhances metastatic potential of human colorectal carcinoma. Arch. Surg. (1990) 125(3):300-304.
   PubMed Web of Science ®Google Scholar
• MINAMI S, FURUI J, KANEMATSU T: Role of carcinoembryonic antigen in the progression of colon cancer cells that express carbohydrate antigen. Cancer Res. (2001) 61(6):2732-2735.
   PubMed Web of Science ®Google Scholar
• ESSAJEE S, KAUFMAN HL: Poxvirus vaccines for cancer and HIV therapy. Expert Opin. Biol. Ther. (2004) 4(4):575-588.
   PubMed Web of Science ®Google Scholar
• EVANS DE, WEINBERG AD: Boosting T cell costimulation in cancer: the possibilities seem endless. Int. Rev. Immunol. (2003) 22(2):173-194.
   PubMed Web of Science ®Google Scholar
• PARKER KC, BEDNAREK MA, COLIGAN JE: Scheme for ranking potential HLA-A2 binding peptides based on independent binding of individual peptide side-chains. J. Immunol. (1994) 152(1):163-175.
   PubMed Web of Science ®Google Scholar
• PARKER KC, SHIELDS M, DIBRINO M, BROOKS A, COLIGAN JE: Peptide binding to MHC class I molecules: implications for antigenic peptide prediction. Immunol. Res. (1995) 14(1):34-57.
   PubMed Web of Science ®Google Scholar
• COLLINS EJ, FRELINGER JA: Altered peptide ligand design: altering immune responses to class I MHC/peptide complexes. Immunol. Rev. (1998) 163:151-160.
   PubMed Web of Science ®Google Scholar
• TSANG KY, PALENA C, GULLEY J, ARLEN P, SCHLOM J: A human cytotoxic T-lymphocyte epitope and its agonist epitope from the nonvariable number of tandem repeat sequence of MUC-1. Clin. Cancer Res. (2004) 10(6):2139-2149.
   PubMed Web of Science ®Google Scholar
• ZAREMBA S, BARZAGA E, ZHU M, SOARES N, TSANG KY, SCHLOM J: Identification of an enhancer agonist cytotoxic T lymphocyte peptide from human carcinoembryonic antigen. Cancer Res. (1997) 57(20):4570-4577.
   PubMed Web of Science ®Google Scholar
• SALAZAR E, ZAREMBA S, ARLEN PM, TSANG KY, SCHLOM J: Agonist peptide from a cytotoxic t-lymphocyte epitope of human carcinoembryonic antigen stimulates production of tc1-type cytokines and increases tyrosine phosphorylation more efficiently than cognate peptide. Int. J. Cancer (2000) 85(6):829-838.
   PubMed Web of Science ®Google Scholar
• WINGREN AG, PARRA E, VARGA M et al.: T cell activation pathways: B7, LFA-3, and ICAM-1 shape unique T cell profiles. Crit. Rev. Immunol. (1995) 15(3-4):235-253.
   PubMed Web of Science ®Google Scholar
• CHEN L, MCGOWAN P, ASHE S et al.: Tumor immunogenicity determines the effect of B7 costimulation on T cell-mediated tumor immunity. J. Exp. Med. (1994) 179(2):523-532.
   PubMed Web of Science ®Google Scholar
• HODGE JW, SABZEVARI H, YAFAL AG, GRITZ L, LORENZ MG, SCHLOM J: A triad of costimulatory molecules synergize to amplify T-cell activation. Cancer Res. (1999) 59(22):5800-5807.
   PubMed Web of Science ®Google Scholar
• OH S, HODGE JW, AHLERS JD, BURKE DS, SCHLOM J, BERZOFSKY JA: Selective induction of high avidity CTL by altering the balance of signals from APC. J. Immunol. (2003) 170(5):2523-2530.
   PubMed Web of Science ®Google Scholar
• HODGE JW, CHAKRABORTY M, KUDO-SAITO C, GARNETT CT, SCHLOM J: Multiple costimulatory modalities enhance CTL avidity. J. Immunol. (2005) 174(10):5994-6004.
   PubMed Web of Science ®Google Scholar
• YANG S, TSANG KY, SCHLOM J: Induction of higher-avidity human CTLs by vector-mediated enhanced costimulation of antigen-presenting cells. Clin. Cancer Res. (2005) 11(15):5603-5615.
   PubMed Web of Science ®Google Scholar
• YANG S, HODGE JW, GROSENBACH DW, SCHLOM J: Vaccines with enhanced costimulation maintain high avidity memory CTL. J. Immunol. (2005) 175(6):3715-3723.
   PubMed Web of Science ®Google Scholar
• DISIS ML, BERNHARD H, SHIOTA FM et al.: Granulocyte-macrophage colony-stimulating factor: an effective adjuvant for protein and peptide-based vaccines. Blood (1996) 88(1):202-210.
   PubMed Web of Science ®Google Scholar
• KASS E, PARKER J, SCHLOM J, GREINER JW: Comparative studies of the effects of recombinant GM-CSF and GM-CSF administered via a poxvirus to enhance the concentration of antigen- presenting cells in regional lymph nodes. Cytokine (2000) 12(7):960-971.
   PubMed Web of Science ®Google Scholar
• KANTOR J, ABRAMS S, IRVINE K, SNOY P, KAUFMAN H, SCHLOM J: Specific immunotherapy using a recombinant vaccinia virus expressing human carcinoembryonic antigen. Ann. NY Acad. Sci. (1993) 690:370-373.
   PubMed Web of Science ®Google Scholar
• KASS E, SCHLOM J, THOMPSON J, GUADAGNI F, GRAZIANO P, GREINER JW: Induction of protective host immunity to carcinoembryonic antigen (CEA), a self-antigen in CEA transgenic mice, by immunizing with a recombinant vaccinia-CEA virus. Cancer Res. (1999) 59(3):676-683.
   PubMed Web of Science ®Google Scholar
• PALENA C, ZHU M, SCHLOM J, TSANG KY: Human B cells that hyperexpress a triad of costimulatory molecules via avipox-vector infection: an alternative source of efficient antigen-presenting cells. Blood (2004) 104(1):192-199.
   PubMed Web of Science ®Google Scholar
• ZHU M, TERASAWA H, GULLEY J et al.: Enhanced activation of human T cells via avipox vector-mediated hyperexpression of a triad of costimulatory molecules in human dendritic cells. Cancer Res. (2001) 61(9):3725-3734.
   PubMed Web of Science ®Google Scholar
• HODGE JW, GROSENBACH DW, RAD AN, GIULIANO M, SABZEVARI H, SCHLOM J: Enhancing the potency of peptide-pulsed antigen presenting cells by vector-driven hyperexpression of a triad of costimulatory molecules. Vaccine (2001) 19(25-26):3552-3567.
   PubMed Web of Science ®Google Scholar
• MOSS B: Genetically engineered poxviruses for recombinant gene expression, vaccination, and safety. Proc. Natl. Acad. Sci. USA (1996) 93(21):11341-11348.
   PubMed Web of Science ®Google Scholar
• ETLINGER HM, ALTENBURGER W: Overcoming inhibition of antibody responses to a malaria recombinant vaccinia virus caused by prior exposure to wild type virus. Vaccine (1991) 9(7):470-472.
   PubMed Web of Science ®Google Scholar
• KUNDIG TM, KALBERER CP, HENGARTNER H, ZINKERNAGEL RM: Vaccination with two different vaccinia recombinant viruses: long-term inhibition of secondary vaccination. Vaccine (1993) 11(11):1154-1158.
   PubMed Web of Science ®Google Scholar
• KONISHI E, PINCUS S, PAOLETTI E, SHOPE RE, WASON PW: Avipox virus-vectored Japanese encephalitis virus vaccines: use as vaccine candidates in combination with purified subunit immunogens. Vaccine (1994) 12(7):633-638.
   PubMed Web of Science ®Google Scholar
• SLACK R, LEY L, CHANG P et al.: Association between CEA-specific T cell responses (TCR) following treatment with vaccinia-CEA (V) and ALVAC-CEA (A) and survival in patients (pts) with CEA-bearing cancers [abstract]. Proc. Am. Soc. Clin. Oncol. (2001) 20(Pt 1):1086.
   Google Scholar
• KAUFMAN HL, WANG W, MANOLA J et al.: Phase II randomized study of vaccine treatment of advanced prostate cancer (E7897): a trial of the Eastern Cooperative Oncology Group. J. Clin. Oncol. (2004) 22(11):2122-2132.
   PubMed Web of Science ®Google Scholar
• KAUFMAN H, WANG W, MANOLA J et al.: Phase II prime/boost vaccination using poxviruses expressing PSA in hormone dependent prostate cancer: follow-up clinical results from ECOG 7897 [abstract]. J. Clin. Oncol. (2005) 23(16S Pt I):4501.
   Web of Science ®Google Scholar
• SCHUETZ T, MARSHALL J, KAUFMAN H, SAFRAN H, PANICALI D: Two Phase I studies of prime-boost vaccinations with vaccinia-fowlpox vaccines expressing CEA, MUC-1, and TRICOM costimulatory molecules (B7.1/ICAM-1/LFA-3) in patients with advanced pancreatic cancer [abstract]. J. Clin. Oncol. (2004) 22(14S):2564.
   Google Scholar
• SCHUETZ T, KAUFMAN H, MARSHALL J, SAFRAN H: Extended survival in second-line pancreatic cancer after therapeutic vaccination [abstract]. J. Clin. Oncol. (2005) 23(16S):2576.
   Google Scholar
• PETRULIO CA, KAUFMAN HL: Development of the PANVAC-VF vaccine for pancreatic cancer. Expert Rev. Vaccines (2006) 5(1):9-19.
   PubMed Web of Science ®Google Scholar
• GULLEY L, ARLEN P, DAHUT W et al.: A pilot study of a PANVAC-V and PANVAC-F in patients (pts) with metastatic carcinoma [abstract]. J. Clin. Oncol. (2006) 24(18S):2512.
   Google Scholar
• MAAS IW, BOVEN E, PINEDO HM, SCHLUPER HM, HAISMA HJ: The effects of gamma-interferon combined with 5-fluorouracil or 5-fluoro-2’-deoxyuridine on proliferation and antigen expression in a panel of human colorectal cancer cell lines. Int. J. Cancer (1991) 48(5):749-756.
   PubMed Web of Science ®Google Scholar
• ABDALLA EE, BLAIR GE, JONES RA, SUE-LING HM, JOHNSTON D: Mechanism of synergy of levamisole and fluorouracil: induction of human leukocyte antigen class I in a colorectal cancer cell line. J. Natl Cancer Inst. (1995) 87(7):489-496.
   PubMed Web of Science ®Google Scholar
• MIZUTANI Y, WU XX, YOSHIDA O, SHIRASAKA T, BONAVIDA B: Chemoimmunosensitization of the T24 human bladder cancer line to Fas-mediated cytotoxicity and apoptosis by cisplatin and 5-fluorouracil. Oncol. Rep. (1999) 6(5):979-982.
   PubMed Web of Science ®Google Scholar
• BERGMANN-LEITNER ES, ABRAMS SI: Treatment of human colon carcinoma cell lines with anti-neoplastic agents enhances their lytic sensitivity to antigen-specific CD8+ cytotoxic T lymphocytes. Cancer Immunol. Immunother. (2001) 50(9):445-455.
   PubMed Web of Science ®Google Scholar
• CARSON WE 3RD, SHAPIRO CL, CRESPIN TR, THORNTON LM, ANDERSEN BL: Cellular immunity in breast cancer patients completing taxane treatment. Clin. Cancer Res. (2004) 10(10):3401-3409.
   PubMed Web of Science ®Google Scholar
• ARLEN PM, GULLEY JL, PARKER C et al.: A randomized Phase II study of concurrent docetaxel plus vaccine versus vaccine alone in metastatic androgen-independent prostate cancer. Clin. Cancer Res. (2006) 12(4):1260-1269.
   PubMed Web of Science ®Google Scholar
• ARLEN PM, PAZDUR M, SKARUPA L, RAUCKHORST M, GULLEY JL: A randomized Phase II study of docetaxel alone or in combination with PANVAC-V (vaccinia) and PANVAC-F (fowlpox) in patients with metastatic breast cancer (NCI 05-C-0229). Clin. Breast Cancer (2006) 7(2):176-179.
   PubMed Web of Science ®Google Scholar
• LOU E, MARSHALL J, AKLILU M, COLE D, CHANG D, MORSE M: A Phase II study of active immunotherapy with PANVAC or autologous, cultured dendritic cells infected with PANVAC after complete resection of hepatic metastases of colorectal carcinoma. Clin. Colorectal Cancer (2006) 5(5):368-371.
   PubMed Web of Science ®Google Scholar
• FOON KA, JOHN WJ, CHAKRABORTY M et al.: Clinical and immune responses in resected colon cancer patients treated with anti-idiotype monoclonal antibody vaccine that mimics the carcinoembryonic antigen. J. Clin. Oncol. (1999) 17(9):2889-2885.
   PubMed Web of Science ®Google Scholar
• CHAKRABORTY M, ABRAMS SI, CAMPHAUSEN K et al.: Irradiation of tumor cells up-regulates Fas and enhances CTL lytic activity and CTL adoptive immunotherapy. J. Immunol. (2003) 170(12):6338-6347.
   PubMed Web of Science ®Google Scholar
• CHAKRABORTY M, ABRAMS SI, COLEMAN CN, CAMPHAUSEN K, SCHLOM J, HODGE JW: External beam radiation of tumors alters phenotype of tumor cells to render them susceptible to vaccine-mediated T-cell killing. Cancer Res. (2004) 64(12):4328-4337.
   PubMed Web of Science ®Google Scholar
• REITS EA, HODGE JW, HERBERTS CA et al.: Radiation modulates the peptide repertoire, enhances MHC class I expression, and induces successful antitumor immunotherapy. J. Exp. Med. (2006) 203(5):1259-1271.
   PubMed Web of Science ®Google Scholar
• GELBARD A, GARNETT CT, ABRAMS SI et al.: Combination chemotherapy and radiation of human squamous cell carcinoma of the head and neck augments CTL-mediated lysis. Clin. Cancer Res. (2006) 12(6):1897-1905.
   PubMed Web of Science ®Google Scholar
• JACOBY RF, SEIBERT K, COLE CE, KELLOFF G, LUBET RA: The cyclooxygenase-2 inhibitor celecoxib is a potent preventive and therapeutic agent in the min mouse model of adenomatous polyposis. Cancer Res. (2000) 60(18):5040-5044.
   PubMed Web of Science ®Google Scholar
• ZEYTIN HE, PATEL AC, ROGERS CJ et al.: Combination of a poxvirus-based vaccine with a cyclooxygenase-2 inhibitor (celecoxib) elicits antitumor immunity and long-term survival in CEA.Tg/MIN mice. Cancer Res. (2004) 64(10):3668-3678.
   PubMed Web of Science ®Google Scholar
• GREINER JW, ZEYTIN H, ANVER MR, SCHLOM J: Vaccine-based therapy directed against carcinoembryonic antigen demonstrates antitumor activity on spontaneous intestinal tumors in the absence of autoimmunity. Cancer Res. (2002) 62(23):6944-6951.
   PubMed Web of Science ®Google Scholar
• PHILLIPS RK, WALLACE MH, LYNCH PM et al.: A randomised, double blind, placebo controlled study of celecoxib, a selective cyclooxygenase 2 inhibitor, on duodenal polyposis in familial adenomatous polyposis. Gut (2002) 50(6):857-860.
   PubMed Web of Science ®Google Scholar
• STEINBACH G, LYNCH PM, PHILLIPS RK et al.: The effect of celecoxib, a cyclooxygenase-2 inhibitor, in familial adenomatous polyposis. N. Engl. J. Med. (2000) 342(26):1946-1952.
   PubMed Web of Science ®Google Scholar
• GUADAGNI F, ROSELLI M, COSIMELLI M et al.: Quantitative analysis of CEA expression in colorectal adenocarcinoma and serum: lack of correlation. Int. J. Cancer (1997) 72(6):949-954.
   PubMed Web of Science ®Google Scholar
• VON MEHREN M, ARLEN P, GULLEY J et al.: The influence of granulocyte macrophage colony-stimulating factor and prior chemotherapy on the immunological response to a vaccine (ALVAC-CEA B7.1) in patients with metastatic carcinoma. Clin. Cancer Res. (2001) 7(5):1181-1191.
   PubMed Web of Science ®Google Scholar
• MOORE M, GOLDSTEIN D, HAMM J et al.: Erlotinib plus gemcitabine compared to gemcitabine alone in patients with advanced pancreatic cancer. A Phase III trial of the National Cancer Institute of Canada Clinical Trials Group (NCIC-CTG) [abstract]. J. Clin. Oncol. (2005) 23(16S Pt I):1.
   PubMed Web of Science ®Google Scholar
• ECKEL F, SCHNEIDER G, SCHMID RM: Pancreatic cancer: a review of recent advances. Expert Opin. Investig. Drugs (2006) 15(11):1395-1410.
   PubMed Web of Science ®Google Scholar
• KINDLER H, NIEDZWIECKI D, HOLLIS D et al.: A double-blind, placebo-controlled, randomized Phase III trial of gemcitabine (G) plus bevacizumab (B) versus gemcitabine plus placebo (P) in patients (pts) with advanced pancreatic cancer (PC): a preliminary analysis of Cancer and Leukemia Group B (CALGB) 80303 [abstract]. 2007 Gastrointestinal Cancers Symposium Program/Proceedings (2007):108.
   Google Scholar
• RATAIN MJ, EISEN T, STADLER WM et al.: Phase II placebo-controlled randomized discontinuation trial of sorafenib in patients with metastatic renal cell carcinoma. J. Clin. Oncol. (2006) 24(16):2505-2512.
   PubMed Web of Science ®Google Scholar
• ROSENBERG SA, LOTZE MT, YANG JC et al.: Prospective randomized trial of high-dose interleukin-2 alone or in conjunction with lymphokine-activated killer cells for the treatment of patients with advanced cancer. J. Natl Cancer Inst. (1993) 85(8):622-632.
   PubMed Web of Science ®Google Scholar
• YANG JC, SHERRY RM, STEINBERG SM et al.: Randomized study of high-dose and low-dose interleukin-2 in patients with metastatic renal cancer. J. Clin. Oncol. (2003) 21(16):3127-3132.
   PubMed Web of Science ®Google Scholar
• YANG JC, HAWORTH L, SHERRY RM et al.: A randomized trial of bevacizumab, an anti-vascular endothelial growth factor antibody, for metastatic renal cancer. N. Engl. J. Med. (2003) 349(5):427-434.
   PubMed Web of Science ®Google Scholar